Instituto de Investigación Sanitaria de Navarra-ko ikertzaileekin lankidetzan egindako argitalpenak (88)

2024

  1. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

    JHEP Reports, Vol. 6, Núm. 1

  2. Application of Graph Models to the Identification of Transcriptomic Oncometabolic Pathways in Human Hepatocellular Carcinoma

    Biomolecules, Vol. 14, Núm. 6

  3. Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis

    JHEP Reports, Vol. 6, Núm. 8

  4. Comprehensive in silico CpG methylation analysis in hepatocellular carcinoma identifies tissue- and tumor-type specific marks disconnected from gene expression

    Journal of Physiology and Biochemistry

  5. Exploring current and emerging therapies for porphyrias

    Liver International, Vol. 44, Núm. 9, pp. 2174-2190

  6. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

  7. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5

  8. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)

    Clinical science (London, England : 1979), Vol. 138, Núm. 20, pp. 1265-1284

  9. Porphyrins and the porphyrias

    Liver International

  10. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia

  11. Refinement of paramagnetic bead-based digestion protocol for automatic sample preparation using an artificial neural network

    Talanta, Vol. 274

  12. SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

    Cell Reports, Vol. 43, Núm. 3

  13. Sweet dreams could be made of this: carbohydrate-responsive element-binding protein (ChREBP) as a target for hepatocellular carcinoma therapy

    Molecular Oncology

  14. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

  15. The Alpha-Lipoic Acid Improves Glucose Metabolism and Hyperinsulinemia in Acute Intermittent Porphyria: A Nutritional Concept for the Management of Rare Disorders

    Cellular and Molecular Gastroenterology and Hepatology

2023

  1. A new FGF15/19-mediated gut-to-heart axis controls cardiac hypertrophy

    Journal of Pathology, Vol. 261, Núm. 3, pp. 335-348

  2. Comprehensive analysis of epigenetic and epitranscriptomic genes’ expression in human NAFLD

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 901-924

  3. Frontiers in fatty liver: recent advances in pathogenic mechanisms, assessment of patients’ prognosis and pharmacotherapy: MASLD: new pathogenic mechanisms, risk assessment tools and drug therapies

    Journal of Physiology and Biochemistry

  4. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  5. Loss of liver function in chronic liver disease: An identity crisis

    Journal of Hepatology, Vol. 78, Núm. 2, pp. 401-414